Iowa House Bill HF182

Iowa 2025-2026 Regular Session

• Introduced: 1/30/25
• Engrossed: 2/20/25
• Enrolled: 3/28/25
• Passed: 3/28/25

Caption

A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions. (Formerly HSB 25.) Effective date: 03/28/2025.

Summary

HF 182 updates Iowa’s controlled substances laws by adding a large number of newly identified synthetic opioids, synthetic cannabinoids, cathinones, and other designer drugs to the state’s controlled substance schedules. The bill specifically places many fentanyl analogs, nitazenes, and related compounds into Schedule I or other applicable schedules, and it also removes a few existing entries from one schedule section while revising several steroid-related listings in another. In addition, it adds zuranolone to the controlled substances framework and makes a technical change to precursor-substance rules involving iodine and N-phenylpiperidin-4-amine (4-AP) derivatives.

Impact

The bill expands the list of substances that are illegal to manufacture, possess, distribute, or traffic under Iowa’s controlled substances chapter, thereby giving law enforcement and prosecutors clearer authority over emerging illicit drugs and analogs. It also modifies precursor-substance reporting and exemption provisions, including a new rule covering chemical mixtures identified as exempt by federal regulation. The changes affect manufacturers, distributors, pharmacies, laboratories, and criminal defendants by broadening the substances subject to scheduling and related penalties, and the act takes effect immediately upon enactment.

Sentiment

The bill appears to have been broadly supported and noncontroversial in the legislature. It passed the House 92-0 and the Senate 47-0, indicating unanimous approval in both chambers. The lack of recorded committee debate or dissent suggests the measure was viewed as a routine but important public-safety update to keep Iowa law aligned with rapidly evolving synthetic drugs.

Contention

No major opposition is reflected in the available record. The main policy issue is the breadth of the scheduling updates, which sweep in many chemically similar compounds and analogs, but the unanimous votes suggest legislators largely agreed that the state needed to close loopholes used by illicit drug manufacturers. Any potential concern would likely center on the technical complexity of the chemical definitions and the possibility of capturing closely related substances used in legitimate research or pharmaceutical contexts, though no specific objections are documented here.